Movano Inc Stock News

Company's first 510(k) clearance unlocks a TAM of $40 billion in healthcare B2B opportunities PLEASANTON, Calif. , Dec. 2, 2024 /PRNewswire/ -- Movano Health  (Nasdaq: MOVE), a pioneer in health technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring.

Movano Inc. (NASDAQ:MOVE ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants J. Cogan - CFO John Mastrototaro - CEO Tyla Bucher - Chief Marketing Officer Michael Soule - Chief Commercial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Operator Ladies and gentlemen, greetings, and welcome to the Movano Health Third Quarter Earnings Conf...

Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. , Nov. 14, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update.

New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- Movano Health Inc. (Nasdaq: MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as part of its November 5 th and 6th hypoxia clinical trial that took place at the University of California, San Francisco.

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif. , Nov. 6, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report third quarter 2024 financial and operating results on Thursday November 14, 2024, after the market close.

Company remains optimistic on the potential for this pioneering healthcare solution PLEASANTON, Calif. , Nov. 4, 2024 /PRNewswire/ -- Movano Health  (NASDAQ:  MOVE ) announced today that it has submitted a complete response package to the FDA as part of the final phase of the Company's 510(k) application review of the EvieMED Ring.

Company Continues to Work with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif. , Nov. 4, 2024 /PRNewswire/ -- Movano Health  (Nasdaq:  MOVE ) (the "Company") provided an update on an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved ...

Company Communicating with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif. , Oct. 31, 2024 /PRNewswire/ --  Movano Health  (Nasdaq:  MOVE ) (the "Company") announced today that it has opened an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholde...